SUPERNUS PHARMACEUTICALS, INC.: net property, plant and equipment

What this measure means

Carrying amount of property, plant and equipment after accumulated depreciation, depletion and amortization. It is not replacement cost or market value.

Exact concept: us-gaap:PropertyPlantAndEquipmentNet. Each value is a balance at the reporting date, not a flow earned over a year. Different units remain separate; no currency conversion or interpolation is applied.

Coverage of this history

Selected reporting periods run from 2011-12-31 to 2025-12-31. The SEC response was captured on 2026-09-20.

Selected filing history

Related financial histories

• SUPERNUS PHARMACEUTICALS, INC.: total assets
• SUPERNUS PHARMACEUTICALS, INC.: total liabilities
• SUPERNUS PHARMACEUTICALS, INC.: stockholders equity
• SUPERNUS PHARMACEUTICALS, INC.: cash and cash equivalents
• SUPERNUS PHARMACEUTICALS, INC.: net income or loss
• SUPERNUS PHARMACEUTICALS, INC.: operating cash flow
• SUPERNUS PHARMACEUTICALS, INC.: capital expenditure payments
• SUPERNUS PHARMACEUTICALS, INC.: revenue
• SUPERNUS PHARMACEUTICALS, INC.: contract revenue excluding tax
• SUPERNUS PHARMACEUTICALS, INC.: financing cash flow
• SUPERNUS PHARMACEUTICALS, INC.: investing cash flow
• SUPERNUS PHARMACEUTICALS, INC.: retained earnings or deficit
• SUPERNUS PHARMACEUTICALS, INC.: basic weighted-average shares
• SUPERNUS PHARMACEUTICALS, INC.: diluted weighted-average shares
• SUPERNUS PHARMACEUTICALS, INC.: basic earnings per share
• SUPERNUS PHARMACEUTICALS, INC.: diluted earnings per share
• SUPERNUS PHARMACEUTICALS, INC.: income tax expense or benefit
• SUPERNUS PHARMACEUTICALS, INC.: share-based compensation expense
• SUPERNUS PHARMACEUTICALS, INC.: operating income or loss
• SUPERNUS PHARMACEUTICALS, INC.: current assets
• SUPERNUS PHARMACEUTICALS, INC.: interest expense
• SUPERNUS PHARMACEUTICALS, INC.: current liabilities
• SUPERNUS PHARMACEUTICALS, INC.: current accounts payable
• SUPERNUS PHARMACEUTICALS, INC.: goodwill carrying amount
• SUPERNUS PHARMACEUTICALS, INC.: net current accounts receivable
• SUPERNUS PHARMACEUTICALS, INC.: net inventory
• SUPERNUS PHARMACEUTICALS, INC.: selling, general and administrative expense
• SUPERNUS PHARMACEUTICALS, INC.: research and development expense

Inspect the source

Entity

SUPERNUS PHARMACEUTICALS, INC. / CIK 0001356576

Captured

2026-09-20T07:55:43.346Z

SEC response SHA-256

e4ffe1415c2b501e2c67d7dc14c0bfee891abde97e80adbe5035738fc4156668

Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON

Latest-filed annual-report facts per unit and reporting period at capture time. Duration facts cover 300 to 400 days. This selection can include restatements and is not a point-in-time backtest dataset. Missing concepts are omitted, never zero-filled. Values retain original units and are not currency converted. Extended concepts require compatible unit shapes and at least three reporting ends with changing values within one unit. Constant or incompatible added histories are omitted.

Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.

Use this in research

A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.

These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.

Research methodology · Execution and cost assumptions · Check backtest overfitting

Build with the open-source tools

Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.

• Get an API key and run your first validation
• Connect the MCP server to your coding assistant
• Inspect the ALPHAC engine on GitHub
• Read the MCP server source and integration examples

import json
from urllib.request import urlopen

with urlopen("https://canlicapital.com/company-data/0001356576.json") as response:
    record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
    print(concept["tag"], next(iter(concept["observations"])))